London, United Kingdom, November 17, 2017 --(PR.com
)-- SMi Group are proud to present the 9th Annual RNA Therapeutics conference, taking place on 21st - 22nd February 2018 at Holiday Inn Kensington Forum, London, UK.
Learn more about:
- How The RNA Institute is using a unique RNA target to engineer a novel antibiotic.
- The opportunities that small activating RNA can bring in drug development.
- How to utilise RNA epigenetics, by targeting RNA modifying enzymes.
- Drafting a successful new patent application for an RNA therapeutic.
- The advances in targeted delivery of nucleotides beyond the liver.
- Targeting liver hepatocytes using alternative delivery approaches with siRNA.
- The important advantages of exosomes as an RNA delivery system, compared to other nanoparticulate systems.
Join the two-day interactive conference in Kensington, London on February 21st – 22nd to learn, explore and network with industry professionals. See the full speaker line-up and packed agenda featuring presentations from The RNA Institute, MHRA, MiNA Therapeutics, AstraZeneca R&D, Sanofi, GSK, CureVac and more. www.therapeutics-rna.com/prc
On Day 1: Examine topics on using RNA for therapeutic opportunities including treating cystic fibrosis, liver cancer and skin diseases, and examine the novel approaches and emerging technologies to support these treatments. Day 2: Explores commercial and regulatory considerations, whilst also examining the developments in delivery systems to direct the therapeutic to their target.
Day 1 Opening Address
The Keynote Address on day 1 will be presented by Paul Agris, Founding Director & Professor at The RNA Institute. Gain a deeper insight into his presentation, "Engineering a Novel Antibiotic Against a Unique RNA Target that Prevents Resistance." His session will be looking at how novel antibiotics can bind to target RNA and prevent resistance with low cytotoxicity and toxicity.
Summary of presentation:
- Target selection unique to Gram positive pathogens.
- Screening tools for putative small molecule, RNA binding antibiotics against Gram positive pathogens and their biofilms.
- Target prevents emergence of resistance.
- Low Cytotoxicity and Toxicity.
Day 2 Opening Address
The Opening Address on day 2 will be presented by Kirsty Wydenbach, Senior Medical Assessor, Deputy Unit Manager, Clinical Trials Unit, at MHRA. Her presentation, "Gaining Regulatory Approval and Mitigating Risks during Clinical Trials," will explore how best to gain regulatory approval and clinical success through overcoming common governing pitfalls and understanding the expectations of regulators.
Summary of presentation:
- Expectations of a regulator and how to report your results.
- Overcoming common governing pitfalls.
- Updates of new and upcoming regulations and how you may be affected.
For those looking to attend there is currently a £200 early-bird saving, ending November 30th.
Further information is available at: www.therapeutics-rna.com/prc
SMi presents the 9th Annual Conference:
Date: 21st – 22nd February 2018
Location: Holiday Inn London - Kensington Forum
Sponsored by: ChemGenes | Phion Therapeutics
For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: email@example.com
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk